{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:24:01Z","timestamp":1790637841432,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST-107-2314-B-002-173-MY2"],"award-info":[{"award-number":["MOST-107-2314-B-002-173-MY2"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    T-cell acute lymphoblastic leukemia (T-ALL) is caused by the accumulation of multiple genetic alterations. To determine the frequency of common genetic mutations and possible prognostic markers in childhood T-ALL, we performed targeted sequencing of 67 genes across 64 cases treated according to Taiwan Pediatric Oncology Group protocols between January 2002 and December 2015. Together, 302 variants were identified in 60 genes including 233 single nucleotide variants and 69 indels. Sixty-four samples had a median number of six genetic lesions each (range 1\u201317). Thirteen genes had mutation frequencies\u2009&gt;\u200910%, and 5 were\u2009&gt;\u200920%, with the highest being\n                    <jats:italic>NOTCH1<\/jats:italic>\n                    (70.31%). Protocadherins\n                    <jats:italic>FAT1<\/jats:italic>\n                    (32.81%) and\n                    <jats:italic>FAT3<\/jats:italic>\n                    (17.19%), and the ubiquitin ligase component\n                    <jats:italic>FBXW7<\/jats:italic>\n                    (28.13%) had higher mutation frequencies than previously reported. Other mutation frequencies (\n                    <jats:italic>PHF6<\/jats:italic>\n                    ,\n                    <jats:italic>DNM2<\/jats:italic>\n                    ,\n                    <jats:italic>DNMT3A, CNOT3<\/jats:italic>\n                    , and\n                    <jats:italic>WT1)<\/jats:italic>\n                    were within previously reported ranges. Three epigenetic-related genes (\n                    <jats:italic>KMT2D<\/jats:italic>\n                    ,\n                    <jats:italic>DNMT3A<\/jats:italic>\n                    , and\n                    <jats:italic>EZH2)<\/jats:italic>\n                    were mutated in our cohort.\n                    <jats:italic>JAK-STAT<\/jats:italic>\n                    signaling pathway genes had mutation frequencies of 3\u201313% and were observed in 23 cases (35.94%). Changes to genes in the ErbB signaling pathway were detected in 20 cases (31.25%). Patients with\n                    <jats:italic>NOTCH1<\/jats:italic>\n                    \/\n                    <jats:italic>FBXW7<\/jats:italic>\n                    mutations and\n                    <jats:italic>RAS<\/jats:italic>\n                    \/\n                    <jats:italic>PTEN<\/jats:italic>\n                    germline exhibited better 5-year overall survival rates.\n                  <\/jats:p>","DOI":"10.1038\/s41598-020-80613-6","type":"journal-article","created":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T14:24:12Z","timestamp":1610461452000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Targeted sequencing to identify genetic alterations and prognostic markers in pediatric T-cell acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"11","author":[{"given":"Ya-Hsuan","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Hsiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiann-Tarng","family":"Jou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Hsin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Yao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang-Hsi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiu-Hao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Tsamn","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Wha","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsuan-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,12]]},"reference":[{"key":"80613_CR1","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1056\/NEJMra052603","volume":"354","author":"CH Pui","year":"2006","unstructured":"Pui, C. H. & Evans, W. E. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 354, 166\u2013178 (2006).","journal-title":"N. Engl. J. Med."},{"key":"80613_CR2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41571-018-0136-6","volume":"16","author":"CH Pui","year":"2019","unstructured":"Pui, C. H., Nichols, K. E. & Yang, J. J. Somatic and germline genomics in paediatric acute lymphoblastic leukaemia. Nat. Rev. Clin. Oncol. 16, 227\u2013240 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"80613_CR3","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","volume":"33","author":"CH Pui","year":"2015","unstructured":"Pui, C. H. et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J. Clin. Oncol. 33, 2938\u20132948 (2015).","journal-title":"J. Clin. Oncol."},{"key":"80613_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1535-6108(02)00018-1","volume":"1","author":"AA Ferrando","year":"2002","unstructured":"Ferrando, A. A. et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1, 75\u201387 (2002).","journal-title":"Cancer Cell"},{"key":"80613_CR5","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.ccr.2011.02.008","volume":"19","author":"I Homminga","year":"2011","unstructured":"Homminga, I. et al. Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell 19, 484\u2013497 (2011).","journal-title":"Cancer Cell"},{"key":"80613_CR6","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1182\/blood-2004-10-3900","volume":"106","author":"J Soulier","year":"2005","unstructured":"Soulier, J. et al. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood 106, 274\u2013286 (2005).","journal-title":"Blood"},{"key":"80613_CR7","doi-asserted-by":"publisher","first-page":"4038","DOI":"10.1182\/blood.V84.12.4038.bloodjournal84124038","volume":"84","author":"J Hebert","year":"1994","unstructured":"Hebert, J., Cayuela, J. M., Berkeley, J. & Sigaux, F. Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood 84, 4038\u20134044 (1994).","journal-title":"Blood"},{"key":"80613_CR8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1126\/science.1102160","volume":"306","author":"AP Weng","year":"2004","unstructured":"Weng, A. P. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306, 269\u2013271 (2004).","journal-title":"Science"},{"key":"80613_CR9","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1084\/jem.20072182","volume":"205","author":"E Flex","year":"2008","unstructured":"Flex, E. et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J. Exp. Med. 205, 751\u2013758 (2008).","journal-title":"J. Exp. Med."},{"key":"80613_CR10","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/ng.924","volume":"43","author":"PP Zenatti","year":"2011","unstructured":"Zenatti, P. P. et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat. Genet. 43, 932\u2013939 (2011).","journal-title":"Nat. Genet."},{"key":"80613_CR11","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1084\/jem.20110580","volume":"208","author":"C Shochat","year":"2011","unstructured":"Shochat, C. et al. Gain-of-function mutations in interleukin-7 receptor-\u03b1 (IL7R) in childhood acute lymphoblastic leukemias. J. Exp. Med. 208, 901\u2013908 (2011).","journal-title":"J. Exp. Med."},{"key":"80613_CR12","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1084\/jem.20112239","volume":"208","author":"P Van Vlierberghe","year":"2011","unstructured":"Van Vlierberghe, P. et al. ETV6 mutations in early immature human T cell leukemias. J. Exp. Med. 208, 2571\u20132579 (2011).","journal-title":"J. Exp. Med."},{"key":"80613_CR13","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nm.2610","volume":"18","author":"G Della Gatta","year":"2012","unstructured":"Della Gatta, G. et al. Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL. Nat. Med. 18, 436\u2013440 (2012).","journal-title":"Nat. Med."},{"key":"80613_CR14","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.1182\/blood-2010-11-318873","volume":"118","author":"A Gutierrez","year":"2011","unstructured":"Gutierrez, A. et al. The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia. Blood 118, 4169\u20134173 (2011).","journal-title":"Blood"},{"key":"80613_CR15","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/nm.2246","volume":"16","author":"K De Keersmaecker","year":"2010","unstructured":"De Keersmaecker, K. et al. The TLX1 oncogene drives aneuploidy in T cell transformation. Nat. Med. 16, 1321\u20131327 (2010).","journal-title":"Nat. Med."},{"key":"80613_CR16","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1182\/blood-2009-07-234377","volume":"115","author":"A Gutierrez","year":"2010","unstructured":"Gutierrez, A. et al. Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood 115, 2845\u20132851 (2010).","journal-title":"Blood"},{"key":"80613_CR17","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/ng.542","volume":"42","author":"P Van Vlierberghe","year":"2010","unstructured":"Van Vlierberghe, P. et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat. Genet. 42, 338\u2013342 (2010).","journal-title":"Nat. Genet."},{"key":"80613_CR18","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1182\/blood-2008-12-192039","volume":"114","author":"V Tosello","year":"2009","unstructured":"Tosello, V. et al. WT1 mutations in T-ALL. Blood 114, 1038\u20131045 (2009).","journal-title":"Blood"},{"key":"80613_CR19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nature10725","volume":"481","author":"J Zhang","year":"2012","unstructured":"Zhang, J. et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481, 157\u2013163 (2012).","journal-title":"Nature"},{"key":"80613_CR20","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/ng.3909","volume":"49","author":"Y Liu","year":"2017","unstructured":"Liu, Y. et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat. Genet. 49, 1211\u20131218 (2017).","journal-title":"Nat. Genet."},{"key":"80613_CR21","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/nrc.2016.63","volume":"16","author":"L Belver","year":"2016","unstructured":"Belver, L. & Ferrando, A. The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat. Rev. Cancer 16, 494\u2013507 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"80613_CR22","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1182\/blood-2016-10-706465","volume":"129","author":"T Girardi","year":"2017","unstructured":"Girardi, T., Vicente, C., Cools, J. & De Keersmaecker, K. The genetics and molecular biology of T-ALL. Blood 129, 1113\u20131123 (2017).","journal-title":"Blood"},{"key":"80613_CR23","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1182\/blood-2005-12-4956","volume":"108","author":"S Breit","year":"2006","unstructured":"Breit, S. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood 108, 1151\u20131157 (2006).","journal-title":"Blood"},{"key":"80613_CR24","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/pbc.24803","volume":"61","author":"L Fogelstrand","year":"2014","unstructured":"Fogelstrand, L. et al. Prognostic implications of mutations in NOTCH1 and FBXW7 in childhood T-all treated according to the NOPHO ALL-1992 and ALL-2000 protocols. Pediatr. Blood Cancer 61, 424\u2013430 (2014).","journal-title":"Pediatr. Blood Cancer"},{"key":"80613_CR25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/leu.2015.206","volume":"30","author":"S Jenkinson","year":"2016","unstructured":"Jenkinson, S. et al. Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial. Leukemia 30, 39\u201347 (2016).","journal-title":"Leukemia"},{"key":"80613_CR26","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1038\/leu.2009.64","volume":"23","author":"A Larson Gedman","year":"2009","unstructured":"Larson Gedman, A. et al. The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: A report from the Children\u2019s Oncology Group. Leukemia 23, 1417\u20131425 (2009).","journal-title":"Leukemia"},{"key":"80613_CR27","doi-asserted-by":"publisher","first-page":"4352","DOI":"10.1200\/JCO.2009.22.0996","volume":"27","author":"MR Mansour","year":"2009","unstructured":"Mansour, M. R. et al. Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-Cell acute lymphoblastic leukemia treated on the MRC UKALLXII\/ECOG E2993 protocol. J. Clin. Oncol. 27, 4352\u20134356 (2009).","journal-title":"J. Clin. Oncol."},{"key":"80613_CR28","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/j.1365-2141.2009.07607.x","volume":"145","author":"M-J Park","year":"2009","unstructured":"Park, M.-J. et al. FBXW7andNOTCH1mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. Br. J. Haematol. 145, 198\u2013206 (2009).","journal-title":"Br. J. Haematol."},{"key":"80613_CR29","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1158\/1078-0432.CCR-05-2832","volume":"12","author":"YM Zhu","year":"2006","unstructured":"Zhu, Y. M. NOTCH1 mutations in T-cell acute lymphoblastic leukemia: Prognostic significance and implication in multifactorial leukemogenesis. Clin. Cancer Res. 12, 3043\u20133049 (2006).","journal-title":"Clin. Cancer Res."},{"key":"80613_CR30","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/nrc.2016.63","volume":"16","author":"L Belver","year":"2016","unstructured":"Belver, L. & Ferrando, A. The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat. Rev. 16, 494\u2013507 (2016).","journal-title":"Nat. Rev."},{"key":"80613_CR31","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1172\/JCI61269","volume":"122","author":"P Van Vlierberghe","year":"2012","unstructured":"Van Vlierberghe, P. & Ferrando, A. The molecular basis of T cell acute lymphoblastic leukemia. J. Clin. Investig. 122, 3398\u20133406 (2012).","journal-title":"J. Clin. Investig."},{"key":"80613_CR32","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.3324\/haematol.2015.130179","volume":"100","author":"C Vicente","year":"2015","unstructured":"Vicente, C. et al. Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia. Haematologica 100, 1301\u20131310 (2015).","journal-title":"Haematologica"},{"key":"80613_CR33","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1200\/JCO.2010.28.3390","volume":"28","author":"A Gutierrez","year":"2010","unstructured":"Gutierrez, A. et al. Absence of biallelic TCR deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia. J. Clin. Oncol. 28, 3816\u20133823 (2010).","journal-title":"J. Clin. Oncol."},{"key":"80613_CR34","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1182\/blood-2009-02-206722","volume":"114","author":"A Gutierrez","year":"2009","unstructured":"Gutierrez, A. et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 114, 647\u2013650 (2009).","journal-title":"Blood"},{"key":"80613_CR35","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/ng.2508","volume":"45","author":"K De Keersmaecker","year":"2013","unstructured":"De Keersmaecker, K. et al. Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nat. Genet. 45, 186\u2013190 (2013).","journal-title":"Nat. Genet."},{"key":"80613_CR36","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/leu.2016.234","volume":"31","author":"CH Pui","year":"2017","unstructured":"Pui, C. H. et al. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with response-adapted therapy. Leukemia 31, 333\u2013339 (2017).","journal-title":"Leukemia"},{"key":"80613_CR37","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/blood-2014-01-547695","volume":"123","author":"K Beldjord","year":"2014","unstructured":"Beldjord, K. et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood 123, 3739\u20133749 (2014).","journal-title":"Blood"},{"key":"80613_CR38","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1182\/blood-2017-04-778829","volume":"131","author":"A Petit","year":"2018","unstructured":"Petit, A. et al. Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia. Blood 131, 289\u2013300 (2018).","journal-title":"Blood"},{"key":"80613_CR39","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3389\/fped.2017.00258","volume":"5","author":"H Inaba","year":"2017","unstructured":"Inaba, H., Azzato, E. M. & Mullighan, C. G. Integration of next-generation sequencing to treat acute lymphoblastic leukemia with targetable lesions: The St. Jude children\u2019s research hospital approach. Front Pediatr 5, 258 (2017).","journal-title":"Front Pediatr"},{"key":"80613_CR40","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","volume":"10","author":"E Coustan-Smith","year":"2009","unstructured":"Coustan-Smith, E. et al. Early T-cell precursor leukaemia: A subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 10, 147\u2013156 (2009).","journal-title":"Lancet Oncol."},{"key":"80613_CR41","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/pbc.26142","volume":"64","author":"M-J Li","year":"2017","unstructured":"Li, M.-J. et al. Treatment for childhood acute lymphoblastic leukemia in Taiwan: Taiwan Pediatric Oncology Group ALL-2002 study emphasizing optimal reinduction therapy and central nervous system preventive therapy without cranial radiation. Pediatr. Blood Cancer 64, 234\u2013241 (2017).","journal-title":"Pediatr. Blood Cancer"},{"key":"80613_CR42","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1111\/j.1349-7006.2011.02031.x","volume":"102","author":"YL Yang","year":"2011","unstructured":"Yang, Y. L. et al. IKZF1 deletions predict a poor prognosis in children with B-cell progenitor acute lymphoblastic leukemia: A multicenter analysis in Taiwan. Cancer Sci. 102, 1874\u20131881 (2011).","journal-title":"Cancer Sci."},{"key":"80613_CR43","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1182\/blood-2007-04-079988","volume":"110","author":"J Bergeron","year":"2007","unstructured":"Bergeron, J. et al. Prognostic and oncogenic relevance of TLX1\/HOX11 expression level in T-ALLs. Blood 110, 2324\u20132330. https:\/\/doi.org\/10.1182\/blood-2007-04-079988 (2007).","journal-title":"Blood"},{"key":"80613_CR44","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/ng.3900","volume":"49","author":"M Seki","year":"2017","unstructured":"Seki, M. et al. Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia. Nat. Genet. 49, 1274\u20131281 (2017).","journal-title":"Nat. Genet."},{"key":"80613_CR45","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/sj.leu.2404957","volume":"22","author":"M van Grotel","year":"2007","unstructured":"van Grotel, M. et al. Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia 22, 124\u2013131 (2007).","journal-title":"Leukemia"},{"key":"80613_CR46","doi-asserted-by":"publisher","first-page":"4333","DOI":"10.1200\/JCO.2012.48.5292","volume":"31","author":"A Trinquand","year":"2013","unstructured":"Trinquand, A. et al. Toward a NOTCH1\/FBXW7\/RAS\/PTEN\u2013based oncogenetic risk classification of adult t-cell acute lymphoblastic leukemia: A group for research in adult acute lymphoblastic leukemia study. J. Clin. Oncol. 31, 4333\u20134342 (2013).","journal-title":"J. Clin. Oncol."},{"key":"80613_CR47","doi-asserted-by":"publisher","first-page":"e274962","DOI":"10.1002\/pbc.27496","volume":"66","author":"T-C Yeh","year":"2019","unstructured":"Yeh, T.-C. et al. Clinical and biological relevance of genetic alterations in pediatric T-cell acute lymphoblastic leukemia in Taiwan. Pediatr. Blood Cancer 66, e274962 (2019).","journal-title":"Pediatr. Blood Cancer"},{"key":"80613_CR48","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.chembiol.2020.04.002","volume":"27","author":"M Marchesini","year":"2020","unstructured":"Marchesini, M. et al. Blockade of oncogenic NOTCH1 with the SERCA inhibitor CAD204520 in T cell acute lymphoblastic leukemia. Cell Chem. Biol. 27, 678-697.e613 (2020).","journal-title":"Cell Chem. Biol."},{"key":"80613_CR49","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1073\/pnas.1611831114","volume":"114","author":"M Sanchez-Martin","year":"2017","unstructured":"Sanchez-Martin, M. et al. Synergistic antileukemic therapies in NOTCH1-induced T-ALL. Proc. Natl. Acad. Sci. 114, 2006\u20132011 (2017).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"80613_CR50","doi-asserted-by":"publisher","first-page":"e350","DOI":"10.1038\/bcj.2015.80","volume":"5","author":"C Papayannidis","year":"2015","unstructured":"Papayannidis, C. et al. A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Blood Cancer J. 5, e350\u2013e350 (2015).","journal-title":"Blood Cancer J."},{"key":"80613_CR51","doi-asserted-by":"publisher","first-page":"e9094","DOI":"10.1371\/journal.pone.0009094","volume":"5","author":"M Aste-Am\u00e9zaga","year":"2010","unstructured":"Aste-Am\u00e9zaga, M. et al. Characterization of notch1 antibodies that inhibit signaling of both normal and mutated notch1 receptors. PLoS ONE 5, e9094 (2010).","journal-title":"PLoS ONE"},{"key":"80613_CR52","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/nature08878","volume":"464","author":"Y Wu","year":"2010","unstructured":"Wu, Y. et al. Therapeutic antibody targeting of individual Notch receptors. Nature 464, 1052\u20131057 (2010).","journal-title":"Nature"},{"key":"80613_CR53","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/cas.14238","volume":"111","author":"C-H Yu","year":"2020","unstructured":"Yu, C.-H. et al. TP53 alterations in relapsed childhood acute lymphoblastic leukemia. Cancer Sci. 111, 229\u2013238 (2020).","journal-title":"Cancer Sci."},{"key":"80613_CR54","doi-asserted-by":"publisher","first-page":"e0221288","DOI":"10.1371\/journal.pone.0221288","volume":"14","author":"GP Pouliot","year":"2019","unstructured":"Pouliot, G. P. et al. Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia. PLoS ONE 14, e0221288 (2019).","journal-title":"PLoS ONE"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80613-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80613-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80613-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T21:02:07Z","timestamp":1670014927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80613-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,12]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["80613"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-80613-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,12]]},"assertion":[{"value":"16 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"769"}}